4月21日，据CDE官网消息，奥辰生物（云南）有限公司联合申请药品“TriCellPr-AC07人脐带间充质干细胞注射液”，获得临床试验默示许可，受理号CXSL2500071。
公示信息显示，药品“TriCellPr-AC07人脐带间充质干细胞注射液”适应症：膝骨关节炎。
奥辰生物（云南）有限公司，成立于2023年，位于昆明市，是一家以从事研究和试验发展为主的企业。企业注册资本5000万人民币，实缴资本3000万人民币。
通过天眼查大数据分析，奥辰生物（云南）有限公司共对外投资了3家企业，参与招投标项目1次，专利信息4条，此外企业还拥有行政许可2个。
主要股东信息显示，奥辰生物（云南）有限公司由奥辰干细胞再生医学工程（云南）有限公司持股100%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.